To help improve reproductive health globally by enabling prevention of HIV and sexually transmitted infections, unintended pregnancies and maternal/neonatal disease through the development of innovative, user-centered technologies suitable for use by people living in resource-constrained regions of the world.
Our accomplishments include:
- Conducted pivotal clinical trials for registration of barrier methods of contraception, most recently the Caya one-size-fits-most diaphragm, which is currently sold in the U.S. and Europe
- CONRAD sponsored late phase studies, including FACTS 001 and CAPRISA 004 which tested the use of tenofovir gel for HIV prevention in women, the male contraceptive trial of TU/NE, and the first generation microbicide trial of cellulose sulfate.
- Developed pipeline of novel male and female contraceptive leads
- Pioneered public/private partnerships in contraceptive R&D
- Designed preclinical models and algorithms for testing products
- Developed new microbicide delivery systems
- Provided product development, manufacturing, and preclinical testing capacity to other organizations (private and public)
- Developed and tested contraceptive, microbicide and dual- protection candidates following an integrated preclinical/clinical system
- Introduced innovation in early candidate assessment